ReviewCureus2025
Evaluation of the Clinical Impact of Immune Checkpoint Inhibitors (Atezolizumab and Pembrolizumab) in the Treatment of Triple-Negative Breast Cancer: A Meta-Analysis and Review of Literature.
Nafees Khan et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.